FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904772908> ?p ?o ?g. }

• W2904772908 endingPage "461" @default.
• W2904772908 startingPage "454" @default.
• W2904772908 abstract "Background In this retrospective study, we investigated the impact of 68Ga-PSMA-11 PET-CT (PSMA PET-CT) upon the treatment plan and therapeutic response obtained for Prostate Cancer (PCa) patients presenting an occult biochemical recurrence. Methods Forty-two patients with previously negative or doubtful 18F-Choline (FCH) were enrolled. PET images were recorded 1 h after injection of tracer. Only a few months after treatment ended, a PSA assay was requested to evaluate the therapeutic efficacy of the treatment based on PSMA results. Results PSMA—positive lesions were detected in 34/42 (80.9%) patients. Detection rates were 85.7% and 89.3% for serum PSA levels lower than 2 ng/mL, and >2 ng/mL, respectively. One hundred seventy-three lesions were detected: 132/173 in lymph nodes (76.3%), 22/173 as metastatic sites (bone or lung) (12.7%), and 19/173 in the prostate bed (10.9%). As a result of the PSMA PET-CT, therapeutic management changed in 31/42 patients (73.8%). With a follow-up of 4.9 ± 2.27 months, 32/42 (76.2%) PSA assays after treatment guided by PSMA PET-CT were collected. For 37.5% (12/32) of patients, the serum PSA level was lower than 0.2 ng/mL and a PSA decrease of over 50% in 8 (25.0%) other patients were obtained. Conclusion Performing a PSMA PET-CT when FCH PET-CT was doubtful or negative allows the recurrence localization in more 80% of patients and this had a major clinical impact, as it resulted in treatment change in more than 70% of patients as well as a significant decrease in PSA levels in more than 60% of them." @default.
• W2904772908 created "2018-12-22" @default.
• W2904772908 creator A5001022411 @default.
• W2904772908 creator A5002836262 @default.
• W2904772908 creator A5013375868 @default.
• W2904772908 creator A5021513670 @default.
• W2904772908 creator A5022695085 @default.
• W2904772908 creator A5029972934 @default.
• W2904772908 creator A5032958001 @default.
• W2904772908 creator A5048377698 @default.
• W2904772908 creator A5055352653 @default.
• W2904772908 creator A5062137018 @default.
• W2904772908 creator A5065080277 @default.
• W2904772908 creator A5067155189 @default.
• W2904772908 creator A5071588217 @default.
• W2904772908 creator A5077470196 @default.
• W2904772908 date "2018-12-14" @default.
• W2904772908 modified "2023-09-30" @default.
• W2904772908 title "68Ga‐PSMA‐11 PET‐CT study in prostate cancer patients with biochemical recurrence and non‐contributive 18F‐Choline PET‐CT: Impact on therapeutic decision‐making and biomarker changes" @default.
• W2904772908 cites W1900676315 @default.
• W2904772908 cites W1978337671 @default.
• W2904772908 cites W1979181356 @default.
• W2904772908 cites W2043601120 @default.
• W2904772908 cites W2057677149 @default.
• W2904772908 cites W2080006760 @default.
• W2904772908 cites W2137670219 @default.
• W2904772908 cites W2257635864 @default.
• W2904772908 cites W2299477037 @default.
• W2904772908 cites W2415076046 @default.
• W2904772908 cites W2511949746 @default.
• W2904772908 cites W2529888262 @default.
• W2904772908 cites W2591849683 @default.
• W2904772908 cites W2618588529 @default.
• W2904772908 cites W2743412658 @default.
• W2904772908 cites W2801398567 @default.
• W2904772908 cites W2886449856 @default.
• W2904772908 doi "https://doi.org/10.1002/pros.23751" @default.
• W2904772908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30549066" @default.
• W2904772908 hasPublicationYear "2018" @default.
• W2904772908 type Work @default.
• W2904772908 sameAs 2904772908 @default.
• W2904772908 citedByCount "15" @default.
• W2904772908 countsByYear W29047729082019 @default.
• W2904772908 countsByYear W29047729082020 @default.
• W2904772908 countsByYear W29047729082021 @default.
• W2904772908 countsByYear W29047729082022 @default.
• W2904772908 countsByYear W29047729082023 @default.
• W2904772908 crossrefType "journal-article" @default.
• W2904772908 hasAuthorship W2904772908A5001022411 @default.
• W2904772908 hasAuthorship W2904772908A5002836262 @default.
• W2904772908 hasAuthorship W2904772908A5013375868 @default.
• W2904772908 hasAuthorship W2904772908A5021513670 @default.
• W2904772908 hasAuthorship W2904772908A5022695085 @default.
• W2904772908 hasAuthorship W2904772908A5029972934 @default.
• W2904772908 hasAuthorship W2904772908A5032958001 @default.
• W2904772908 hasAuthorship W2904772908A5048377698 @default.
• W2904772908 hasAuthorship W2904772908A5055352653 @default.
• W2904772908 hasAuthorship W2904772908A5062137018 @default.
• W2904772908 hasAuthorship W2904772908A5065080277 @default.
• W2904772908 hasAuthorship W2904772908A5067155189 @default.
• W2904772908 hasAuthorship W2904772908A5071588217 @default.
• W2904772908 hasAuthorship W2904772908A5077470196 @default.
• W2904772908 hasBestOaLocation W29047729082 @default.
• W2904772908 hasConcept C121608353 @default.
• W2904772908 hasConcept C126322002 @default.
• W2904772908 hasConcept C126838900 @default.
• W2904772908 hasConcept C127077266 @default.
• W2904772908 hasConcept C142724271 @default.
• W2904772908 hasConcept C185592680 @default.
• W2904772908 hasConcept C204787440 @default.
• W2904772908 hasConcept C2775842073 @default.
• W2904772908 hasConcept C2776235491 @default.
• W2904772908 hasConcept C2776256026 @default.
• W2904772908 hasConcept C2777714996 @default.
• W2904772908 hasConcept C2780192828 @default.
• W2904772908 hasConcept C2781197716 @default.
• W2904772908 hasConcept C2989005 @default.
• W2904772908 hasConcept C520017518 @default.
• W2904772908 hasConcept C55493867 @default.
• W2904772908 hasConcept C71924100 @default.
• W2904772908 hasConceptScore W2904772908C121608353 @default.
• W2904772908 hasConceptScore W2904772908C126322002 @default.
• W2904772908 hasConceptScore W2904772908C126838900 @default.
• W2904772908 hasConceptScore W2904772908C127077266 @default.
• W2904772908 hasConceptScore W2904772908C142724271 @default.
• W2904772908 hasConceptScore W2904772908C185592680 @default.
• W2904772908 hasConceptScore W2904772908C204787440 @default.
• W2904772908 hasConceptScore W2904772908C2775842073 @default.
• W2904772908 hasConceptScore W2904772908C2776235491 @default.
• W2904772908 hasConceptScore W2904772908C2776256026 @default.
• W2904772908 hasConceptScore W2904772908C2777714996 @default.
• W2904772908 hasConceptScore W2904772908C2780192828 @default.
• W2904772908 hasConceptScore W2904772908C2781197716 @default.
• W2904772908 hasConceptScore W2904772908C2989005 @default.
• W2904772908 hasConceptScore W2904772908C520017518 @default.
• W2904772908 hasConceptScore W2904772908C55493867 @default.
• W2904772908 hasConceptScore W2904772908C71924100 @default.
• W2904772908 hasIssue "5" @default.

• next